We’re setting the pace for future drug discovery by driving innovation from within
Intractable cancers using
Multiple cancers such as gut, liver and pancreatic cancers are associated with poor prognosis with low 6-month survival rates. Our idea is to use our expertise in multi-targeting to create a library of potentially synergistic target pairs. The designed ligands could then offer greater efficacy and larger population coverage of different genotypes.
Liver cancer is typically associated with poor outcomes. The current state of the art are kinase inhibitors that work by inhibiting growth factor pathways. We are designing ligands targeting two independent pathways that have been validated to play a part in liver cancer. The program is currently at the design stage.